William Pickering
Stock Analyst at Bernstein
(1.76)
# 3,156
Out of 5,149 analysts
33
Total ratings
47.62%
Success rate
-1.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by William Pickering
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $90 → $94 | $58.53 | +60.60% | 6 | Feb 25, 2026 | |
| BEAM Beam Therapeutics | Maintains: Outperform | $37 → $41 | $27.22 | +50.62% | 2 | Jan 21, 2026 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | n/a | $474.27 | - | 6 | Jan 12, 2026 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | $94 | $64.53 | +45.67% | 1 | Dec 11, 2025 | |
| BHVN Biohaven | Downgrades: Market Perform | $34 → $9 | $10.67 | -15.65% | 3 | Nov 6, 2025 | |
| BIIB Biogen | Maintains: Market Perform | $155 → $157 | $184.02 | -14.68% | 1 | Nov 3, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Market Perform | $14 → $15 | $13.61 | +6.58% | 2 | Oct 28, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $753 → $781 | $766.66 | +1.87% | 3 | Aug 27, 2025 | |
| SRPT Sarepta Therapeutics | Initiates: Market Perform | $13 | $15.87 | -18.08% | 1 | Jul 29, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $314 → $310 | $318.65 | -2.71% | 2 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $27 → $24 | $64.10 | -62.56% | 2 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $78.66 | - | 2 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $6 | $2.53 | +137.15% | 1 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $44 | $58.06 | -24.22% | 1 | Mar 21, 2023 |
BioMarin Pharmaceutical
Feb 25, 2026
Maintains: Outperform
Price Target: $90 → $94
Current: $58.53
Upside: +60.60%
Beam Therapeutics
Jan 21, 2026
Maintains: Outperform
Price Target: $37 → $41
Current: $27.22
Upside: +50.62%
Vertex Pharmaceuticals
Jan 12, 2026
Upgrades: Outperform
Price Target: n/a
Current: $474.27
Upside: -
BridgeBio Pharma
Dec 11, 2025
Initiates: Outperform
Price Target: $94
Current: $64.53
Upside: +45.67%
Biohaven
Nov 6, 2025
Downgrades: Market Perform
Price Target: $34 → $9
Current: $10.67
Upside: -15.65%
Biogen
Nov 3, 2025
Maintains: Market Perform
Price Target: $155 → $157
Current: $184.02
Upside: -14.68%
Intellia Therapeutics
Oct 28, 2025
Downgrades: Market Perform
Price Target: $14 → $15
Current: $13.61
Upside: +6.58%
Regeneron Pharmaceuticals
Aug 27, 2025
Maintains: Outperform
Price Target: $753 → $781
Current: $766.66
Upside: +1.87%
Sarepta Therapeutics
Jul 29, 2025
Initiates: Market Perform
Price Target: $13
Current: $15.87
Upside: -18.08%
Alnylam Pharmaceuticals
Jan 7, 2025
Maintains: Outperform
Price Target: $314 → $310
Current: $318.65
Upside: -2.71%
Nov 29, 2024
Maintains: Market Perform
Price Target: $27 → $24
Current: $64.10
Upside: -62.56%
Jun 14, 2024
Upgrades: Market Perform
Price Target: n/a
Current: $78.66
Upside: -
Mar 21, 2023
Initiates: Market Perform
Price Target: $6
Current: $2.53
Upside: +137.15%
Mar 21, 2023
Initiates: Market Perform
Price Target: $44
Current: $58.06
Upside: -24.22%